RMTI · Rockwell Medical, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $14.44M | - | $13.65M | $13.57M | $15.87M | - | $22.08M | $21.28M | $19.61M | - |
| Gross Profit | $2.90M | - | $2.27M | $2.50M | $3.04M | - | $6.24M | $4.55M | $3.06M | - |
| R&D | - | - | $0 | $0 | $0 | - | $0 | $0 | $18.0K | - |
| SG&A | $3.81M | - | $3.33M | $3.28M | $3.69M | - | $3.58M | $3.45M | $3.78M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $511.0K | - | $400.0K | $400.0K | $539.0K | - | $400.0K | $400.0K | $545.0K | - |
| Operating Income | ($1.48M) | - | ($1.58M) | ($1.35M) | ($1.36M) | - | $1.94M | $515.0K | ($1.32M) | - |
| Interest Expense | $282.0K | - | $285.0K | $276.0K | $431.0K | - | $302.0K | $232.0K | $431.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.60M) | - | ($1.75M) | ($1.49M) | ($1.51M) | - | $1.66M | $343.0K | ($1.73M) | - |
| EPS - Basic | ($0.04) | - | ($0.05) | ($0.05) | ($0.04) | - | $0.05 | $0.01 | ($0.06) | - |
| EPS - Diluted | ($0.04) | - | ($0.05) | ($0.05) | ($0.04) | - | $0.04 | $0.01 | ($0.06) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.61M | $10.71M | $13.61M | $12.48M | $11.39M | $15.66M | $12.34M | $11.86M | $6.64M | $8.98M |
| Accounts Receivable | $8.82M | $8.14M | $8.33M | $8.08M | $9.67M | $8.29M | $8.89M | $10.84M | $11.09M | $10.90M |
| Inventory | $3.06M | $3.42M | $3.96M | $4.16M | $5.04M | $5.78M | $5.89M | $5.88M | $6.07M | $5.87M |
| Accounts Payable | $3.45M | $2.00M | $1.52M | $1.50M | $1.93M | $2.87M | $2.61M | $3.35M | $4.92M | $4.52M |
| Current Assets | $36.94M | $38.16M | $37.51M | $31.61M | $33.03M | $37.03M | $34.22M | $29.75M | $26.70M | $28.77M |
| Total Assets | $57.42M | $57.15M | $57.49M | $52.63M | $53.96M | $59.21M | $57.08M | $53.03M | $50.72M | $52.17M |
| Current Liabilities | $9.87M | $9.58M | $9.58M | $10.95M | $11.21M | $14.09M | $14.18M | $14.89M | $14.95M | $16.64M |
| Long-term Debt | $8.21M | $8.83M | $8.74M | $8.65M | $8.56M | $8.47M | $8.38M | $8.29M | $8.27M | $8.29M |
| Total Liabilities | $21.57M | $20.16M | $20.47M | $22.22M | $22.44M | $26.62M | $27.95M | $29.53M | $30.08M | $30.88M |
| Stockholders' Equity | $35.86M | $36.98M | $37.02M | $30.41M | $31.52M | $32.59M | $29.14M | $23.50M | $20.64M | $21.29M |
| Retained Earnings | ($404.60M) | ($402.99M) | ($402.44M) | ($400.69M) | ($399.19M) | ($397.68M) | ($396.92M) | ($398.59M) | ($398.93M) | ($397.20M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($167.0K) | - | - | - | ($3.49M) | - | - | - | ($2.38M) | - |
| Investing Cash Flow | ($122.0K) | - | - | - | ($1.0K) | - | - | - | ($139.0K) | - |
| Financing Cash Flow | ($813.0K) | - | - | - | ($783.0K) | - | - | - | $178.0K | - |
| CapEx | $425.0K | - | - | - | $139.0K | - | - | - | - | - |
| Free Cash Flow | ($592.0K) | - | - | - | ($3.63M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.37 | - | - | - | 2.39 | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.8% | - | -3.0% | -2.8% | -2.8% | - | 2.9% | 0.6% | -3.4% | - |
| Return on equity | -4.5% | - | -4.7% | -4.9% | -4.8% | - | 5.7% | 1.5% | -8.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.74 | 3.98 | 3.92 | 2.89 | 2.95 | 2.63 | 2.41 | 2.00 | 1.79 | 1.73 |
| Quick ratio | 3.43 | 3.63 | 3.50 | 2.51 | 2.50 | 2.22 | 2.00 | 1.60 | 1.38 | 1.38 |
| Cash ratio | 0.97 | 1.12 | 1.42 | 1.14 | 1.02 | 1.11 | 0.87 | 0.80 | 0.44 | 0.54 |
| Leverage | ||||||||||
| Debt / Equity | 0.23 | 0.24 | 0.24 | 0.28 | 0.27 | 0.26 | 0.29 | 0.35 | 0.40 | 0.39 |
| Debt / Assets | 0.14 | 0.15 | 0.15 | 0.16 | 0.16 | 0.14 | 0.15 | 0.16 | 0.16 | 0.16 |
| Debt / EBITDA | - | - | - | - | - | - | 3.59 | 9.07 | - | - |
| Interest coverage | -5.2x | - | -5.6x | -4.9x | -3.2x | - | 6.4x | 2.2x | -3.1x | - |
| Equity multiplier | 1.60 | 1.55 | 1.55 | 1.73 | 1.71 | 1.82 | 1.96 | 2.26 | 2.46 | 2.45 |
| Liabilities / Assets | 0.38 | 0.35 | 0.36 | 0.42 | 0.42 | 0.45 | 0.49 | 0.56 | 0.59 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 4.73 | - | 3.44 | 3.26 | 3.15 | - | 3.75 | 3.62 | 3.23 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 77d | - | 106d | 112d | 116d | - | 97d | 101d | 113d | - |
| Days payable outstanding | 87d | - | 41d | 40d | 44d | - | 43d | 57d | 92d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | 99.3x | 176.0x | - | - |
| P / B | 1.0x | - | 1.2x | 1.0x | 1.2x | - | 4.4x | 2.4x | 2.4x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | 53.4x | 57.7x | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -4.8% | - | -63.6% | -45.0% | -0.7% | - | 183.3% | 340.5% | 17.9% | - |
| Operating income growth (YoY) | -8.8% | - | - | - | -2.7% | - | - | - | 7.2% | - |
| Net income growth (YoY) | -5.9% | - | - | - | 12.5% | - | - | - | 1.1% | - |
| EPS growth (YoY) | 0.0% | - | - | - | 33.3% | - | - | - | 40.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 83.7% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 13.8% | 13.5% | 27.1% | 29.4% | 52.7% | 53.1% | 35.4% | 146.6% | 64.6% | 50.9% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ROCKWELL MEDICAL against the 5 most active filers in the same SIC group.